Hamilton Wealth LLC acquired a new position in shares of InMode Ltd. (NASDAQ:INMD – Get Rating) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 14,498 shares of the healthcare company's stock, valued at approximately $422,000.

Other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its stake in InMode by 122.3% during the first quarter. JPMorgan Chase & Co. now owns 79,333 shares of the healthcare company's stock worth $2,928,000 after purchasing an additional 43,646 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of InMode by 3.9% during the first quarter. Bank of New York Mellon Corp now owns 110,994 shares of the healthcare company's stock worth $4,095,000 after buying an additional 4,217 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of InMode by 22.6% during the first quarter. PNC Financial Services Group Inc. now owns 13,087 shares of the healthcare company's stock worth $484,000 after buying an additional 2,416 shares in the last quarter. Natixis Advisors L.P. increased its holdings in shares of InMode by 6.1% during the first quarter. Natixis Advisors L.P. now owns 18,591 shares of the healthcare company's stock worth $686,000 after buying an additional 1,076 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of InMode during the first quarter worth $925,000. 55.24% of the stock is currently owned by institutional investors.

InMode Stock Performance

NASDAQ:INMD traded down $0.09 on Wednesday, hitting $35.19. The stock had a trading volume of 42,213 shares, compared to its average volume of 2,201,727. The stock has a market cap of $2.93 billion, a P/E ratio of 17.04 and a beta of 2.19. InMode Ltd. has a 1 year low of $20.60 and a 1 year high of $54.68. The firm's fifty day simple moving average is $35.87 and its two-hundred day simple moving average is $33.10.

Analyst Ratings Changes

Several brokerages have recently issued reports on INMD. Jefferies Financial Group began coverage on shares of InMode in a report on Wednesday, October 12th. They set a "buy" rating and a $40.00 price target for the company. TheStreet downgraded InMode from a "b-" rating to a "c+" rating in a report on Tuesday, September 20th. Finally, Barclays began coverage on InMode in a report on Wednesday, December 21st. They issued an "overweight" rating and a $44.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, InMode has an average rating of "Buy" and a consensus target price of $46.17.

About InMode

(Get Rating)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

Further Reading

• Get a free copy of the StockNews.com research report on InMode (INMD)
• J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
• Is Intel Stock On The Verge Of Breaking Out?
• Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
• Can Alaska Air Continue Soaring Above The Airline Industry?
• Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?

Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMD – Get Rating).

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.